Related Experiment Video
Updated: Mar 26, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
New Management Strategies in Heart Failure
Anjali Tiku Owens1, Susan C Brozena1, Mariell Jessup2
1From the Cardiovascular Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Recent advancements offer new hope for chronic heart failure patients. Two new drugs, ivabradine and sacubitril/valsartan, approved in 2015, target heart failure with reduced ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
- Translational Medicine
Background:
- Chronic heart failure treatment saw limited new drug approvals between 2005 and 2015.
- Existing therapies offered modest improvements for a condition with a poor prognosis.
Purpose of the Study:
- To review recent advancements in heart failure pharmacotherapy.
- To highlight newly approved drugs and emerging treatment strategies for heart failure.
Main Methods:
- Review of clinical trial data and regulatory approvals.
- Synthesis of research on novel therapeutic mechanisms in heart failure.
Main Results:
- The US Food and Drug Administration approved two new drugs in 2015: ivabradine and sacubitril/valsartan (LCZ696).
- These novel therapies target chronic heart failure with reduced ejection fraction, offering new physiological approaches.
Conclusions:
- Recent drug approvals signal a paradigm shift in heart failure management.
- Ongoing research explores innovative strategies for various stages of the heart failure syndrome.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy V: Interprofessional Care
Heart Failure IV: Classification and Diagnostic Evaluation

